These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25499288)

  • 21. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
    de Melo JV; Vieira de Melo MS; Abad MH
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.
    Kim S; Cayre A; Jary M; Jacquin M; Arbez-Gindre F; Fein F; Lakkis Z; Nguyen T; Borg C
    Clin Colorectal Cancer; 2016 Dec; 15(4):e229-e234. PubMed ID: 27600470
    [No Abstract]   [Full Text] [Related]  

  • 24. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
    Loupakis F; Schirripa M; Caparello C; Funel N; Pollina L; Vasile E; Cremolini C; Salvatore L; Morvillo M; Antoniotti C; Marmorino F; Masi G; Falcone A
    Br J Cancer; 2013 Jun; 108(12):2549-56. PubMed ID: 23703247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raltitrexed combined with bevacizumab in heavily pretreated metastatic colorectal cancer.
    Cheng K; Chen Y; Li LH; Liu JY
    J Cancer Res Ther; 2013; 9(4):727-9. PubMed ID: 24518728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
    Venook AP; Blanke CD; Niedzwiecki D; Lenz HJ; Taylor JR; Hollis DR; Sutherland S; Goldberg RM
    Clin Colorectal Cancer; 2005 Nov; 5(4):292-4. PubMed ID: 16356309
    [No Abstract]   [Full Text] [Related]  

  • 27. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
    Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Maspero F; Sauta MG; Beretta GD; Barni S
    Clin Colorectal Cancer; 2013 Sep; 12(3):145-51. PubMed ID: 23763824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic therapy for colorectal cancer.
    Meyerhardt JA; Mayer RJ
    N Engl J Med; 2005 Feb; 352(5):476-87. PubMed ID: 15689586
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
    Vamvakas L; Athanasiadis A; Karampeazis A; Kakolyris S; Polyzos A; Kouroussis Ch; Ziras N; Kalbakis K; Georgoulias V; Souglakos J
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):61-70. PubMed ID: 19729318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent disease four years after surgery and adjuvant chemotherapy.
    Pozzo C; Barone C
    Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
    Sunakawa Y; Schirripa M; Lenz HJ
    Crit Rev Oncol Hematol; 2016 Apr; 100():117-26. PubMed ID: 26850575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current stages of adjuvant treatment of colon cancer.
    Köhne CH
    Ann Oncol; 2012 Sep; 23 Suppl 10():x71-6. PubMed ID: 22987996
    [No Abstract]   [Full Text] [Related]  

  • 34. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
    Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
    Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
    Cremolini C; Marmorino F; Loupakis F; Masi G; Antoniotti C; Salvatore L; Schirripa M; Boni L; Zagonel V; Lonardi S; Aprile G; Tamburini E; Ricci V; Ronzoni M; Pietrantonio F; Valsuani C; Tomasello G; Passardi A; Allegrini G; Di Donato S; Santini D; Falcone A;
    BMC Cancer; 2017 Jun; 17(1):408. PubMed ID: 28599628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant treatment of colon cancer: what is next?
    Van Loon K; Venook AP
    Curr Opin Oncol; 2011 Jul; 23(4):403-9. PubMed ID: 21537178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Eng C; Abbruzzese JL
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):592-8. PubMed ID: 16163242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.